



RECEIVED

NOV 02 2001

TECH CENTER 1600/2900

Atty. Dkt. No. P63763US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: SCHLINGENSIEPEN et al

Appl. No.: 09/341,700

Group Art Unit 1635

Filed: September 24, 1999

Examiner Zara

For: AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD

#22/K.T.
11/2/01
Election

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Commissioner of Patents
Washington, DC 20231

Sir:

Applicant submits the instant paper in response to the Office Action mailed July 30, 2001.

REMARKS

According to the instant Office Action, claims 35-51 are allegedly subject to Restriction Under 35 U.S.C. § 121. According to the Restriction Requirement, a single sequence must be elected from among the SEQ ID numbers recited in present claim 47.

Pursuant to the Restriction Requirement, Applicants elect SEQ ID NO: 1754, i.e., fascin (appearing in application Figure 5-12), with traverse.

Traverse is maintained in that claims 35-46 and 48-51 are improperly included in the requirement for Restriction. Of the pending claims, only claim 47 recites (positively) biological sequences identified by SEQ ID numbers; and the separate molecules represented by the SEQ ID numbers are the only allegedly separate and distinct inventions identified in the Restriction Requirement. Since none of claims 35-46 and 48-51 recites the allegedly separate and distinct